Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

EMU007361

Sigma-Aldrich

MISSION® esiRNA

targeting mouse Cdc42ep2

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41105324
NACRES:
NA.51
Pricing and availability is not currently available.

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CAGCTCTCCAAAGGGACTTGCATCCATCTAGAAGAGAGGAGGGTGTATTCACCACCCTGTCTTTGTTGGCCTTTAATCTAACTTTACCTGACACCTTGGGCCAACTTTGATCACATCTCACCCTCTACTTTTGTTTTGTTTTTGGCAAGAGTGGACATTGGCCCTCTGGAGCCTGTTTTGGGCAGAGGGTGTTGAGAGAGTACTGAGGACTGAGCGGCCAGGACTGTGTGCTGAAGTCACCATGTCCACCAAGGTCCCCATCTATTTGAAACGTGGCAGCCGCAAAGGCAAGAAAGAGAAGCTTCGGGACCTGCTGTCCTCAGACATGATCAGCCCACCACTTGGGGACTTCCGTCACACTATTCACATTGGCAGCGGTGGCGGAGATGACATGTTTGGGGACATCTCCTTC

Ensembl | mouse accession no.

ENSMUSG00000045664

NCBI accession no.

NM_026772

shipped in

ambient

storage temp.

−20°C

Gene Information

mouse ... CDC42EP2(104252), Cdc42ep2(104252)

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
EHU015981EMU003391EMU005061
MISSION® esiRNA targeting mouse Cdc42ep2

EMU007361

MISSION® esiRNA

MISSION® esiRNA targeting human CDC42EP2

EHU015981

MISSION® esiRNA

MISSION® esiRNA targeting mouse Arap3

EMU003391

MISSION® esiRNA

MISSION® esiRNA targeting mouse Acly

EMU005061

MISSION® esiRNA

esiRNA cDNA target sequence

CAGCTCTCCAAAGGGACTTGCATCCATCTAGAAGAGAGGAGGGTGTATTCACCACCCTGTCTTTGTTGGCCTTTAATCTAACTTTACCTGACACCTTGGGCCAACTTTGATCACATCTCACCCTCTACTTTTGTTTTGTTTTTGGCAAGAGTGGACATTGGCCCTCTGGAGCCTGTTTTGGGCAGAGGGTGTTGAGAGAGTACTGAGGACTGAGCGGCCAGGACTGTGTGCTGAAGTCACCATGTCCACCAAGGTCCCCATCTATTTGAAACGTGGCAGCCGCAAAGGCAAGAAAGAGAAGCTTCGGGACCTGCTGTCCTCAGACATGATCAGCCCACCACTTGGGGACTTCCGTCACACTATTCACATTGGCAGCGGTGGCGGAGATGACATGTTTGGGGACATCTCCTTC

esiRNA cDNA target sequence

TCAGAAGAGTTTGCCGTCCTTTGGGGAGAACGTGATTTTTGTTATCTCAGCCCACTGACTTCATTGATCTCTAATCTTTTTTAATTCCTTGGGCCAACTTTGTTCGTGCCCCCACACTGTAGCCAGAAGCCCGTTGGCGAGCTCTGGCACCTGCAAACCACCCCGTGGAACGAGTGTTTCCTCTGGCTGAGGGTTGGAGAGGAGGTGTGGTCTCAGCAGGCGGCCCGTAGCCTCACAGCCAGGCCTGGTGGTGAGGTCACCATGTCCACCAAGGTGCCCATCTATCTGAAGCGTGGCAGTCGCAAGGGCAAGAAGGAGAAGCTTCGGGACCTGCTGTCCTCGGACATGATCAGCCCACCGCTGGGGGACTTCCGCCACACCATTCATATTGGCAGTGGCGGCGGCAGTGACATGTTTGGCGACATC

esiRNA cDNA target sequence

GCGCCTGGAGAAGTACAAAGAAGTGATTAGCTGCCTGCCTCGAGTCAACCGCAGAACACTGGCCACCCTCATCGGGCATCTGTACCGGGTGCAGAAGTGTGCGTCTCTAAACCAGATGTGCACGCGGAACCTGGCCCTACTGTTTGCACCTAGTGTGTTCCAGACAGATGGGCGGGGAGAGCATGAGGTTCGGGTACTGCAGGAGCTCATCGATGGCTACATCTCTGTTTTTGATATTGACTCGGACCAGGCAGCTCAGATTGACTTGGAGGTCAGTCTCATTACCACCTGGAAGGATGTGCAGTTGTCCCAGGCTGGAGACCTCATCATGGAGGTTTACATAGAACAGCAGCTCCCGGACAACTGTGTCACCCTAAAGGTATCCCCAACACTGACTGCTGAGGA

esiRNA cDNA target sequence

CATCGGCCATCGAGTAAAATCGATAAACAACCCAGACATGCGAGTGCAGATCCTCAAGGACTTCGTCAAACAGCACTTCCCCGCCACCCCGCTGCTCGACTATGCCCTGGAAGTGGAGAAGATTACCACCTCCAAGAAGCCAAATCTTATCCTGAATGTGGACGGCTTCATCGGCGTTGCGTTTGTGGACATGCTCAGGAACTGTGGCTCCTTCACCCGGGAGGAAGCTGATGAATATGTTGACATTGGAGCCCTCAATGGCATCTTTGTGCTAGGAAGGAGTATGGGCTTCATTGGGCACTACCTTGACCAGAAGAGGCTGAAGCAAGGGCTGTATCGTCACCCCTGGGATGACATTTCCTATGTTCTTCCAGAACACATGAGCATGTAACTGAGCCAGGAGCCCTA

Gene Information

mouse ... CDC42EP2(104252), Cdc42ep2(104252)

Gene Information

human ... CDC42EP2(10435), CDC42EP2(10435)

Gene Information

mouse ... ARAP3(106952), Arap3(106952)

Gene Information

mouse ... ACLY(104112), Acly(104112)

Ensembl | mouse accession no.

ENSMUSG00000045664

Ensembl | mouse accession no.

-

Ensembl | mouse accession no.

ENSMUSG00000024451

Ensembl | mouse accession no.

ENSMUSG00000020917

product line

MISSION®

product line

MISSION®

product line

MISSION®

product line

MISSION®

form

lyophilized powder

form

lyophilized powder

form

lyophilized powder

form

lyophilized powder

NCBI accession no.

NM_026772

NCBI accession no.

NM_006779

NCBI accession no.

NM_139206

NCBI accession no.

NM_134037

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rong Chen et al.
Biochemistry, 57(18), 2704-2710 (2018-04-14)
Molecular dynamics simulations are employed to determine the inhibitory mechanisms of three drugs, 5-(4-phenoxybutoxy)psoralen (PAP-1), vernakalant, and flecainide, on the voltage-gated K+ channel Kv1.5, a target for the treatment of cardiac arrhythmia. At neutral pH, PAP-1 is neutral, whereas the
Jonas Goldin Diness et al.
Circulation. Arrhythmia and electrophysiology, 10(10) (2017-10-12)
Evidence has emerged that small-conductance Ca2+-activated K+ (SK) channels constitute a new target for treatment of atrial fibrillation (AF). SK channels are predominantly expressed in the atria as compared with the ventricles. Various marketed antiarrhythmic drugs are limited by ventricular
Gerrit Frommeyer et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 19(5), 866-873 (2016-10-06)
The antiarrhythmic drug vernakalant exerts antiarrhythmic effects in atrial fibrillation. Recent experimental data suggest interactions with the late sodium current and antiarrhythmic effects in ventricular arrhythmias. We aimed at investigating whether treatment with vernakalant reduces polymorphic ventricular tachycardia (VT) in
Toshiki Chiba et al.
Journal of pharmacological sciences, 130(3), 170-176 (2016-04-02)
Electrical remodeling plays a pivotal role in maintaining the reentry during atrial fibrillation. In this study, we assessed influence of electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits. We used an atrial electrical remodeling model of the
Gerrit Frommeyer et al.
Journal of cardiovascular medicine (Hagerstown, Md.), 18(9), 663-668 (2017-07-12)
Current guidelines recommend vernakalant for pharmacologic cardioversion of recent-onset atrial fibrillation. However, this drug is not established as chronic therapy. In total, 15 rabbit hearts were Langendorff-perfused. A burst pacing protocol-induced atrial fibrillation in 7 of 15 hearts at baseline

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service